When was Elastagen founded?

Elastagen was founded in 2003 and raised its 1st funding round 2 years after it was founded.

Where is Elastagen located?

Elastagen is headquartered in Sydney, Australia.

How many employees does Elastagen have?

As of Jul 31, 2026, the latest employee count at Elastagen is 2.

Is Elastagen a funded company?

Elastagen is a funded company, having raised a total of $14.7M across 6 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on 2005.

When was the latest funding round of Elastagen?

Elastagen's latest funding was a $***** Grant (prize money) round on Oct 11, 2016, with participation from 0 investor. Its primary sector is Life Sciences Platforms and Tools. Globally, the Life Sciences Platforms and Tools sector has seen $2.48B in funding in 2026 to date.

Where does Elastagen rank among its competitors?

Elastagen ranks 253rd amongst 1955 active competitors, of which 451 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was LifeMine Therapeutics, which secured $75M in Aug, 2026.

Who are the top competitors of Elastagen?

Elastagen's top competitors include Antheia, Transcenta and Akeso. Among them, LifeMine Therapeutics secured the most recent funding round in August, 2026.

Elastagen - 2026 Company Profile, Funding & Competitors

Q: Is Elastagen an acquired company?

Elastagen got acquired by Allergan on Feb 07, 2018.

Company Details

Elastagen is a clinical stage medical company with a pipeline of formulation products based on the human protein tropoelastin.The company was founded after the acquisition of the Elastin technology from its founding scientist Prof Weiss (who is also the company's Lead Scientific Advisor) and his team at the University of Sydney. The Elastin technology offers a new pathway to produce a synthetic, identical and recombinant version of the naturally found "tropoelastin", the building blocks of elastin, a critical component in tissues responsible for the ability of lungs, skin, arteries and other elastic ligaments to stretch and recoil. The company claims that it is the first and only provider of commercial cGMP clinical grade human tropoelastin which can be used to support cell growth and tissue repair. Elastagen also claims the recombinant tropoelastin has an ideal biocompatibility profile and no immune rejection problems. Currently, the company is conducting pivotal clinical studies an injectable dermo-aesthetic product that supposedly restores the elasticity of the skin. In addition, it is investigating solutions for Atrophic Scars, Scar Revision and wound healing. Elastagen claims that its technology has potential applications in skin rejuvenation, scar remodelling and tissue repair. The company also has operations in Europe and UK.

Website: elastagen.com
Social
Email ID: *****@elastogen.com

Key Metrics

Founded Year

2003

Location

Sydney, Australia

Stage

Acquired

Total Funding

$14.7M in 6 rounds

Latest Funding Round

Grant (prize money), Oct 11, 2016, $*****

Investors

Wellcome Trust & 8 more

Ranked

253^rd among 1955 active competitors

Employee Count

2 as on Jul 31, 2026

Similar Companies

Antheia & 2663 more

Exit Details

Acquired by Allergan (Feb 07, 2018)

View Elastagen's full profile

Elastagen got acquired by Allergan on Feb 07, 2018 at an acquisition amount of $*****.

Click here to take a look at Elastagen's acquisition in detail

Elastagen has raised a total funding of $14.7M over 6 rounds. Its first funding round was on 2005. Elastagen has 9 institutional investors.

Here is the list of recent funding rounds of Elastagen:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 11, 2016	2803338	Grant (prize money)	6024216	8478337	2474309	6577243
Jun 21, 2016	7997987	Series B	3857762	8820228	4113366	Cell Innovation Partners
Jan 07, 2016	8925522	Series B	1950008	6918058	Wellcome Trust & 2 more	GBS & 2 more

Access funding benchmarks and valuations. Sign up today!

View details of Elastagen's funding rounds and investors

Elastagen's employee count trend

Elastagen has 2 employees as of Jul 26. Here is Elastagen's employee count trend over the years:

Uncover Elastagen's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Elastagen include Antheia, Transcenta and Akeso. Here is the list of Top 10 competitors of Elastagen, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Antheia 2013, Palo Alto (United States), Series C	Genetically engineered yeast cells to produce medicinal products	$176M	Viking Global Investors, ATHOS KG & 15 others	67/100
2nd	Transcenta 2019, Suzhou (China), Public	Developer of antibody-based therapeutics	$205M	Lilly Asia Ventures, Sequoia Capital & 11 others	66/100
3rd	Akeso 2012, Zhongshan (China), Public	Developer of antibody drug conjugates for the treatment of broad spectrum diseases	$195M	Orbimed, Sino Biopharmaceutical & 18 others	65/100
4th	Korro Bio 2018, Cambridge (United States), Public	Provider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases	$4M	Cormorant Asset Management, Atlas Venture ... & 14 others	64/100
5th	Fermentalg 2005, Libourne (France), Public	Innovating with algae for sustainable solutions in nutrition and environmental impact	$30.3M	Demeter, Smalt Capital & 14 others	63/100
6th	Microban 1994, Huntersville (United States), Acquired	Antimicrobial and odor control technologies for durable product protection and freshness	$64.6M	TA Associates, UBS & 1 others	63/100
7th	LifeMine Therapeutics 2016, Watertown (United States), Series E	Developer of novel drugs from fungi via genome mining and recombinant overexpression	$563M	Fidelity Investments, 6 Dimensions Capital ... & 17 others	63/100
8th	Dewpoint Therapeutics 2018, Boston (United States), Series D	Developer of small molecule based therapeutics	$364M	Maverick Ventures, SoftBank Vision Fund & 16 others	62/100
9th	One Biosciences 2020, Paris (France), Series A	Developer of single-cell therapeutics solutions to treat multiple health disorders	$22.4M	BLAST Premier, Redmile Group & 6 others	62/100
10th	Avalyn Pharma 2011, Seattle (United States), Public	Developer of therapies for the treatment of Idiopathic Pulmonary Fibrosis	$389M	Perceptive Advisors, F-Prime Capital & 22 others	61/100
253rd	Elastagen 2003, Sydney (Australia), Acquired	Company offering solutions for cell growth and tissue repair through their Elastin technology	$14.7M	GBS, ATP-Innovations & 7 others	40/100